FGL2

Predicted protein structure

Clinical relevance (Genomics England PanelApp)

Moderate Evidence (Amber)

• Primary immunodeficiency or monogenic inflammatory bowel disease

  BIALLELIC, autosomal or pseudoautosomal

Disease associations (Open Targets)

• neurodegenerative disease

  0.33

• autoinflammatory syndrome

  0.18

• neoplasm

  0.12

• infection

  0.10

• cancer

  0.10

• colitis

  0.10

• central nervous system cancer

  0.09

• glioma

  0.09

• preeclampsia

  0.09

• Nephropathy

  0.09

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)